Crohn's disease trials in China

In China 73 Also abroad 422

73 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

No phaseNot yet taking people in China
Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease
Where
Guangzhou
Age
18 years and over
People
185
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07344428
No phaseTaking people
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
Where
Shanghai
Age
18 years to 85 years
People
198
Run by
Shanghai 10th People's Hospital
See details and how to joinNCT07694674
No phaseTaking people
Surgery vs Biologics for Treating Stricturing CD--a RCT
Where
Nanjing
Age
18 years to 60 years
People
138
Run by
Zhu Weiming
See details and how to joinNCT05421455
No phaseTaking people
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease
Where
Guangzhou
Age
18 years to 75 years
People
665
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07545317
No phaseTaking people
IBD Biomarker Discovery and Validation Platform
Where
Guangzhou
Age
14 years and over
People
6,000
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07686406
Phase 2Not yet taking people in China
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
Where
Beijing, Bengbu, Changsha, Chongqing, Fujian, Guangzhou, Hefei, Huizhou, Jiujiang, Shaoguan, Shenyang, Shenzhen, Shiyan, Wuhan, Zhengzhou, Zhuzhou
Age
18 years to 75 years
People
156 worldwide
Run by
Jiangsu Carephar Pharmaceutical Co., Ltd.
See details and how to joinNCT07677514
Phase 4Taking people
TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response
Where
Guangzhou
Age
18 years to 65 years
People
312
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07510191
Phase 2Taking people
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Where
Chongqing, Guangdong, Guangzhou, Shanghai
Age
18 years to 75 years
People
192 worldwide
Run by
Takeda
See details and how to joinNCT06764615 · EU 2024-518914-18-00
Phase 1Taking people
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Where
Bengbu, Changchun, Changsha, Guangzhou, Harbin, Hengyang, Huizhou, Kunming, Luoyang, Luzhou, Meihekou, Nanjing, Nanyang, Shanghai, Shenyang, Taishan, Taiyuan, Taizhou, Tianjin, Ürümqi, Wuhan, Wuwei, Zhengzhou
Age
18 years to 75 years
People
135
Run by
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT06754891
Phase 3Taking people
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Beijing, Changsha, Hangzhou, Shanghai, Zhengzhou
Age
2 years to 17 years
People
240 worldwide
Run by
Takeda
See details and how to joinNCT05442567 · EU 2023-509046-36-00
Phase 3Taking people
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Where
Beijing, Hangzhou, Shanghai, Zhengzhou
Age
2 years to 17 years
People
120 worldwide
Run by
Takeda
See details and how to joinNCT04779320 · EU 2023-509045-13-00
Phase 4Taking people
Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety
Where
Guangzhou
Age
18 years to 65 years
People
200
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT07216014
Phase 1/2Not yet taking people in China
BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
Where
Zhongshan
Age
18 years to 70 years
People
18
Run by
iCell Gene Therapeutics
See details and how to joinNCT07544160
No phaseTaking people
Clinical Value of Intestinal Ultrasound in Predicting Clinical Relapse in Crohn's Disease Patients in Deep Remission: a Multicenter Prospective Observational Study
Where
Guangzhou
Age
18 years to 70 years
People
420
Run by
Nanfang Hospital, Southern Medical University
See details and how to joinNCT07539727
No phaseNot yet taking people in China
An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection
Where
Shanghai
Age
18 years and over
People
88
Run by
Shanghai 10th People's Hospital
See details and how to joinNCT07528040
No phaseTaking people
Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial
Where
Shanghai
Age
16 years to 75 years
People
106
Run by
Shanghai Institute of Acupuncture, Moxibustion and Meridian
See details and how to joinNCT06553053
No phaseTaking people
A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab
Where
Hangzhou
Age
18 years to 75 years
People
60
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07487480
Phase 4Taking people
Combined Immunosuppression for Pediatric Crohn's Disease
Where
Shanghai
Age
6 years to 18 years
People
128
Run by
Children's Hospital of Fudan University
See details and how to joinNCT05043870
No phaseTaking people
Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
Where
Hangzhou
Age
18 years to 80 years
People
100
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07444060
No phaseTaking people
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
Where
Beijing, Chongqing, Guangzhou, Hangzhou, Huai'an, Suzhou, Yangzhou
Age
18 years to 65 years
People
239
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT05387031
Phase 4Taking people
Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease
Where
Guangzhou
Age
18 years to 70 years
People
214
Run by
Sixth Affiliated Hospital, Sun Yat-sen University
See details and how to joinNCT06520397
No phaseNot yet taking people in China
The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children
Where
Hangzhou, Jinhua, Kunming, Wenzhou
Age
6 years to 18 years
People
154
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07424040
No phaseTaking people
Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD
Where
Hangzhou
Age
14 years to 80 years
People
300
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07385131
No phaseTaking people
Specific Dietary Pattern for Crohn's Disease Patients Following Surgery
Where
Hangzhou
Age
14 years and over
People
35
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT05502965
No phaseTaking people
Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease
Where
Guangzhou
Age
18 years to 65 years
People
1,400
Run by
Xiang Gao
See details and how to joinNCT07364734